by Richard Daverman, PhD
September 17, 2013 -- Tianjin CanSino Biotechnology has received a $10 million strategic investment from Lilly Asia Ventures, a venture capital arm of Lilly. CanSino specializes in the R&D and manufacture of human vaccines. CanSino will use the capital for R&D, clinical research and early stage commercialization of core combined DPT (diphtheria, pertussis and tetanus) vaccines and several other innovative vaccines. CanSino seeks to develop and market leading-edge, high quality vaccines for China and other emerging markets at an affordable cost. More details....
Stock Symbol: (NYSE: LLY)
Help employers find you! Check out all the jobs and post your resume.
